Bajaj Healthcare Peer Comparison

NSE: BAJAJHCARE | BSE: 539872

₹312.85

₹-1.60 (-0.51%)

As on 29-Oct-2026IST

Market cap

₹1,056 Cr

Revenue (TTM)

₹656 Cr

P/E Ratio

42.3

P/B Ratio

1.9

Div. Yield

0.5 %

Edit

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Market cap (₹ Cr)	1,056	12,883	12,730	6,556	5,620
Revenue (₹ Cr)	656	1,170	710	2,286	722
Net Profit (₹ Cr)	20.61	279.64	188.64	188.43	137.30
Net Margin (%)	3.77	22.94	25.69	8.15	18.17
RoE (%)	11.28	13.92	20.46	14.35	13.79
Price to Earnings	42.31	45.61	67.59	34.77	42.11
Price-To-Book	1.90	6.21	13.30	4.75	5.83

Income Statement (₹ Cr)

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Operating Revenue	655.82	1,170.41	709.64	2,285.51	722.29
Total Income	662.12	1,218.73	734.34	2,311.65	755.49
Total Expenditure	542.50	766.14	458.93	2,009.09	509.38
EBITDA	113.32	404.27	250.72	276.42	212.91
Depreciation	29.49	74.77	17.12	34.55	37.35
EBIT	83.83	329.50	233.59	241.87	175.56
Interest	23.52	0.24	8.49	18.23	29.73
Other Income	6.31	48.32	24.69	26.14	33.20
Exceptional Items	-33.25	-3.28	0.00	0.00	0.00
Profit before Tax	33.37	374.31	249.79	249.78	179.03
Provision for Tax	8.41	94.68	61.16	61.34	41.73
Profit after Tax	24.96	279.64	188.64	188.43	137.30

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Shareholder's Funds	557.16	2,075.76	957.32	1,381.13	1,002.98
Minority Interest	0.00	3.07	-0.30	0.05	-3.82
Non-Current Liabilities	99.59	53.38	106.92	198.11	237.48
Current Liabilities	324.40	201.71	248.88	725.93	411.59
Total Liabilities	923.22	2,231.79	1,174.38	1,936.12	1,603.81

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Non-Current Assets	249.46	980.16	534.87	689.62	867.04
Current Assets	572.28	1,290.68	723.33	1,439.96	766.31
Total Assets	923.22	2,231.79	1,174.38	1,936.12	1,603.81
Total Debt*	233.46	0.00	148.29	194.69	327.09
Net Current Assets	247.88	1,088.97	474.44	714.03	354.72
Contingent Liabilities	23.56	3.76	--	335.40	24.43

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Cash From Operating Activities	58.08	266.88	69.55	32.64	62.05
Cash Flow from Investing Activities	-47.78	-142.72	-330.93	-123.42	-120.56
Cash from Financing Activities	24.33	-112.88	247.29	97.40	-1.33
Net Cash Inflow / Outflow	34.63	11.28	-14.09	6.62	-59.84

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
ROCE (%)	7.04	18.04	28.50	10.19	15.66
ROE (%)	11.28	13.92	20.46	14.35	13.79
ROA (%)	2.74	12.86	16.29	9.32	9.25
EBIT Margin (%)	12.78	28.15	32.92	10.58	24.31
Net Margin (%)	3.77	22.94	25.69	8.15	18.17
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Revenue Growth (%)	14.25	4.02	26.57	30.20	43.39
EBIT Growth (%)	45.14	-11.95	26.37	164.21	90.76
Net Profit Growth (%)	-51.23	-12.44	24.97	89.48	60.23
EPS Growth (%)	14.62	-12.06	8.48	149.66	53.23
Book Value Growth (%)	18.59	11.27	79.97	7.80	18.71

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Price / Earnings	16.77	45.14	68.70	34.77	44.68
Price / Book Value	1.88	6.20	13.52	4.75	6.19
Dividend Yield (%)	0.48	0.61	0.13	0.17	0.00
EV/EBITDA	10.98	30.78	51.74	24.09	28.80
Market Cap (₹ Cr)	975.39	10,627.92	6,690.53	1,851.92	3,490.16

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Debt to Equity	0.13	0.00	0.07	0.09	0.21
Short term debt to equity ratio	0.31	--	0.12	0.03	0.03
Current Ratio	1.76	6.40	2.91	1.98	1.86
Quick Ratio	1.03	4.43	1.80	1.54	1.62
Interest Coverage	2.42	1,593.82	30.42	14.70	7.02

	Bajaj Healthcare	Concord Biotech	Sudeep Pharma	Morepen Lab	Senores Pharmaceuticals
Debtors to sales (%)	38.37	35.24	34.68	15.07	35.06
Asset Turnover	0.72	0.54	0.61	1.13	0.49
Receivable days	145.02	169.86	115.16	66.49	129.44
Inventory Days	112.87	97.92	96.15	57.79	42.09
Payable days	124.08	159.68	106.08	116.46	218.97
Cash Conversion Cycle	133.80	108.11	105.23	7.82	-47.43

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.